ClinicalTrials.Veeva

Menu

Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics

T

Tel Aviv Sourasky Medical Center

Status

Unknown

Conditions

Parkinson Disease

Study type

Observational

Funder types

Other

Identifiers

NCT01089283
TASMC-10-EES-087-CTIL

Details and patient eligibility

About

Parkinson disease is one of the most common neurodegenerative illnesses. The disease is characterized by decrease in dopamine levels and decrease in the number of dopaminergic neurons and dopamine receptors. There are gene mutations that increase the risk for the disease. Two of those mutations are on the LRRK2 gene and on GBA gene. It is yet unknown if there is a difference between the metabolic brain function of Parkinson patients that carry one of the two mutations to Parkinson patients with no known mutation.

Participants: diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes, Parkinson patients with no known mutation and healthy volunteers as a control group.

The participants will go through both examinations DAT SCAN and PET CT SCAN at the Tel Aviv Sourasky Medical Center Nuclear Medicine Institute.

The examination results will be given to the participants by a doctor from the neurology department.

Enrollment

80 estimated patients

Sex

All

Ages

40 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • diagnosed Parkinson patients with known genetic characteristics

Exclusion criteria

  • patients unable to understand and sign an informed consent
  • minors
  • patients in medical condition that does not allow them to stay still during the examination

Trial design

80 participants in 4 patient groups

LRRK2 mutation
Description:
Parkinson patients that carry mutation on LRRK2 gene
GBA mutation
Description:
Parkinson patients that carry mutation on GBA gene
no mutation
Description:
Parkinson patients that don't carry mutation on LRRK2 or GBA genes
healthy
Description:
Healthy volunteers

Trial contacts and locations

1

Loading...

Central trial contact

Einat Even-sapir, PhD, MD; Ayelet Kurzband, BA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems